The rationale for DAO inhibitors as a treatment for schizophrenia has come from their potential to increase D-serine availability, thus correcting the postulated NMDA receptor co-agonist deficiency (Marek et al., 2010; Verrall et al., 2010; Labrie et al., 2012). Here, DAO is linked to schizophrenia.